With so much hype around coronavirus vaccine stocks, it was easy to miss Personalis (NASDAQ: PSNL) , which became a 10-bagger after the market crash last year. Personalis is a biotech that competes with Guardant Health (NASDAQ: GH) and Adaptive Biotechnologies (NASDAQ: ADPT) in the cancer genomics space. The company provides DNA sequencing to drug companies researching pharmaceuticals. Other major competitors include NanoString Technologies (NASDAQ: NSTG) and Foundation Medicine, a subsidiary of Roche Holdings (OTC: RHHBY) .
Personalis is an underdog in cancer genomics, according to Mr. Market, who has assigned the stock the smallest market cap out of this group. And when the stock market crashed last March, Personalis was hit hardest. The stock cratered all the way to $4.27 a share.
You probably wouldn't have bought at the exact bottom, but let's suppose you did. With $10,000, you could have bought 2,341 shares on March 17. At a recent price of $43, your $10,000 Personalis investment would now be worth around a cool $100,700. Not a bad gain in 10 months!
For further details see:
If You Invested $10,000 in Personalis in the Coronavirus Crash, This Is How Much You'd Have Now